Early Study Findings Lead to FDA Breakthrough Therapy Designation for CAR-T Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.
Read More
